Shopping Cart
- Remove All
- Your shopping cart is currently empty
TAS2940 is an irreversible pan-ERBB inhibitor with enhanced brain penetration, utilized for treating lung cancer brain metastases and glioblastomas with HER2/EGFR exon 20 insertions and EGFR abnormalities. In intracranial xenograft models of HER2/EGFR cancers, TAS2940 has demonstrated efficacy in improving survival rates in mice. Currently, TAS2940 is undergoing Phase I clinical trials to establish the maximum tolerated dose for solid tumors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | TAS2940 is an irreversible pan-ERBB inhibitor with enhanced brain penetration, utilized for treating lung cancer brain metastases and glioblastomas with HER2/EGFR exon 20 insertions and EGFR abnormalities. In intracranial xenograft models of HER2/EGFR cancers, TAS2940 has demonstrated efficacy in improving survival rates in mice. Currently, TAS2940 is undergoing Phase I clinical trials to establish the maximum tolerated dose for solid tumors. |
Alias | TAS-2940, TAS2940, TAS 2940 |
Molecular Weight | 482.58 |
Formula | C28H30N6O2 |
Cas No. | 2451398-65-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.